Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

por Pavelka, Karel, Kivitz, Alan, Dokoupilova, Eva, Blanco, Ricardo, Maradiaga, Marco, Tahir, Hasan, Pricop, Luminita, Andersson, Mats, Readie, Aimee, Porter, Brian
Publicado 2017

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study

por Kivitz, Alan J., Nash, Peter, Tahir, Hasan, Everding, Andrea, Mann, Heřman, Kaszuba, Andrzej, Pellet, Pascale, Widmer, Albert, Pricop, Luminita, Abrams, Ken
Publicado 2019

Inhibition of Interleukin 10 Signaling after Fc Receptor Ligation and during Rheumatoid Arthritis

por Ji, Jong-Dae, Tassiulas, Ioannis, Park-Min, Kyung-Hyun, Aydin, Ani, Mecklenbräuker, Ingrid, Tarakhovsky, Alexander, Pricop, Luminita, Salmon, Jane E., Ivashkiv, Lionel B.
Publicado 2003

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

por Mease, Philip J, Kavanaugh, Arthur, Reimold, Andreas, Tahir, Hasan, Rech, Jürgen, Hall, Stephen, Geusens, Piet, Pellet, Pascale, Delicha, Evie Maria, Mpofu, Shephard, Pricop, Luminita
Publicado 2018

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study

por Mease, Philip J., Kavanaugh, Arthur, Reimold, Andreas, Tahir, Hasan, Rech, Juergen, Hall, Stephen, Geusens, Piet, Pellet, Pascale, Delicha, Eumorphia Maria, Pricop, Luminita, Mpofu, Shephard
Publicado 2019

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

por McInnes, Iain B, Mease, Philip J, Ritchlin, Christopher T, Rahman, Proton, Gottlieb, Alice B, Kirkham, Bruce, Kajekar, Radhika, Delicha, Eumorphia-Maria, Pricop, Luminita, Mpofu, Shephard
Publicado 2017

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

por Nash, Peter, Mease, Philip J., McInnes, Iain B., Rahman, Proton, Ritchlin, Christopher T., Blanco, Ricardo, Dokoupilova, Eva, Andersson, Mats, Kajekar, Radhika, Mpofu, Shephard, Pricop, Luminita
Publicado 2018

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

por McInnes, Iain B., Mease, Philip J., Schett, Georg, Kirkham, Bruce, Strand, Vibeke, Williams, Nicole, Fox, Todd, Pricop, Luminita, Jugl, Steffen M., Gandhi, Kunal K.
Publicado 2018

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

por van der Heijde, Désirée, Landewé, Robert B., Mease, Philip J., McInnes, Iain B., Conaghan, Philip G., Pricop, Luminita, Ligozio, Greg, Richards, Hanno B., Mpofu, Shephard
Publicado 2016

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of poole...

por Schreiber, Stefan, Colombel, Jean-Frederic, Feagan, Brian G, Reich, Kristian, Deodhar, Atul A, McInnes, Iain B, Porter, Brian, Das Gupta, Ayan, Pricop, Luminita, Fox, Todd
Publicado 2019

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis

por Pournara, Effie, Kormaksson, Matthias, Nash, Peter, Ritchlin, Christopher T, Kirkham, Bruce W, Ligozio, Gregory, Pricop, Luminita, Ogdie, Alexis, Coates, Laura C, Schett, Georg, McInnes, Iain B
Publicado 2021

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arth...

por Mease, Philip, van der Heijde, Désirée, Kirkham, Bruce, Schett, Georg, Orbai, Ana-Maria, Ritchlin, Christopher, Merola, Joseph F., Pricop, Luminita, James, David A., Zhu, Xuan, Ligozio, Gregory
Publicado 2022

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

por Mease, Philip, van der Heijde, Désirée, Landewé, Robert, Mpofu, Shephard, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Meiser, Karin, Readie, Aimee, Pricop, Luminita, Abrams, Ken
Publicado 2018

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTUR...

por Mease, Philip J, Landewé, Robert, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Readie, Aimee, Mpofu, Shephard, Delicha, Eumorphia Maria, Pricop, Luminita, van der Heijde, Desirée
Publicado 2021

Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials

por Gottlieb, Alice B., Mease, Philip J., Kirkham, Bruce, Nash, Peter, Balsa, Alejandro C., Combe, Bernard, Rech, Jürgen, Zhu, Xuan, James, David, Martin, Ruvie, Ligozio, Gregory, Abrams, Ken, Pricop, Luminita
Publicado 2021

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

por van der Heijde, Désirée, Mease, Philip J, Landewé, Robert B M, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Zhu, Xuan, Ligozio, Gregory, Readie, Aimee, Mpofu, Shephard, Pricop, Luminita
Publicado 2020

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

por Coates, Laura C., Wallman, Johan K., McGonagle, Dennis, Schett, Georg A., McInnes, Iain B., Mease, Philip J., Rasouliyan, Lawrence, Quebe-Fehling, Erhard, Asquith, Darren L., Fasth, Andreas E. R., Pricop, Luminita, Gaillez, Corine
Publicado 2019

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Cl...

por GOTTLIEB, Alice B., DEODHAR, Atul, MCINNES, Iain B., BARALIAKOS, Xenofon, REICH, Kristian, SCHREIBER, Stefan, BAO, Weibin, MARFO, Kwaku, RICHARDS, Hanno B., PRICOP, Luminita, SHETE, Abhijit, TRIVEDI, Vivek, KEEFE, Deborah, PAPAVASSILIS, Charis C., JAGIELLO, Piotr, PAPANASTASIOU, Philemon, MEASE, Philip J., LEBWOHL, Mark
Publicado 2022

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

por Brunner, Hermine I, Foeldvari, Ivan, Alexeeva, Ekaterina, Ayaz, Nuray Aktay, Calvo Penades, Inmaculada, Kasapcopur, Ozgur, Chasnyk, Vyacheslav G, Hufnagel, Markus, Żuber, Zbigniew, Schulert, Grant, Ozen, Seza, Rakhimyanova, Adelina, Ramanan, Athimalaipet, Scott, Christiaan, Sozeri, Betul, Zholobova, Elena, Martin, Ruvie, Zhu, Xuan, Whelan, Sarah, Pricop, Luminita, Martini, Alberto, Lovell, Daniel, Ruperto, Nicolino
Publicado 2023